Background: Information regarding growth hormone (GH) therapy in neonatal patients with methylmalonic acidemia (MMA) is lacking. We present our experience with GH therapy in neonatal patients with MMA. Methods: Four neonatal patients with mut 0 type MMA were identified through newborn screening for elevated propionylcarnitine (C3) levels. GH therapy (0.6 IU/kg/week, subcutaneously) was prescribed for patient 1 after 1 month of admission, and was prescribed for patients 2, 3 and 4 on the 1 st day of admission. We evaluated weight, skin erosion, hospital stay, and serum levels of C3 after GH therapy.
Introduction
Methylmalonic acidemia (MMA) is a rare metabolic disorder that is inherited as an autosomal recessive trait, occurring in 1:50,000 to 1:80,000 newborns. 1 MMA encompasses a heterogeneous group of disorders that are characterized by impaired metabolism of methylmalonic acid that is generated during the metabolism of certain amino acids (isoleucine, methionine, threonine, and valine), odd-chain fatty acids and cholesterol. 2 These disorders are due to a deficiency of the adenosylcobalamin-dependent enzyme methylmalonyl-CoA mutase (MCM, EC 5.4.99.2) or a defect in cobalamin metabolism. 2 At least 8 different complementation groups (mut 0 , mut -, cblA, cblB, cblC, cblD, cblF, and cblH) cause MMA. 3 Patients with the mut 0 defect have undetectable MCM activity, and typically present during the newborn period. 4 Most of these patients with mut 0 type of MMA may die early, before a diagnosis can be made, and those who survive often have a complicated clinical course with significant neurodevelopmental handicap. 5 Conventional therapy of MMA consists of dietary management, which can be supplemented with special formula that does not contain isoleucine, methionine, threonine or valine, L-carnitine supplementation, and inhibition of intestinal bacterial propionate production with oral antibiotics. 6 Furthermore, successful peritoneal dialysis has been reported in neonatal MMA patients with hyperammonemia, 7, 8 and hemodialysis is strongly suggested nowadays. 1 However, poor feeding, poor growth, and intractable skin erosions are common findings in patients with MMA despite aggressive management with conventional therapy. 9 Growth hormone (GH) therapy was shown to be beneficial in growth and metabolic control in a 4.5-year-old boy 9 and in an 11.9-year-old girl, 10 both of whom had mut 0 type MMA. However, GH therapy has never been reported in neonatal patients with MMA. Therefore, we present our experience with 4 neonatal MMA (mut 0 type) patients who were managed with conventional and GH therapies, and clinically evaluate the beneficial effects of GH therapy in neonatal MMA patients.
Methods

Patient reports Patient 1
This male neonate was born to healthy non-consanguineous Taiwanese parents at 40 weeks of gestation and weighed 2,920 g. Poor activity with elevated serum levels of propionylcarnitine (C3, 19.18 μM; normal, < 7 μM) and elevated C3/acetylcarnitine ratio (C3/C2, 1.18; normal, < 0.25) detected by newborn screening using tandem mass spectrometry (MS/MS) were noted at 5 days of age. The patient was then referred to our hospital for confirmatory testing and management.
On admission, he was mildly dehydrated and lethargic. The results of laboratory investigations performed on admission are shown in Table 1 . These laboratory findings demonstrated the presence of leukopenia, anemia, ketotic hypoglycemia, hyperammonemia, metabolic acidosis, and hyperglycinemia, which were compatible with organic acidemia. Organic acid analysis of urine demonstrated increased excretion of methylmalonic acid, leading to the diagnosis of MMA. The mut MMA phenotype was established by measuring MCM activity in lymphocytes from the patient's peripheral blood. MCM activity was undetectable in the patient's lymphocytes (< 0.05 nmol/min/mg protein vs. the normal control value of 3.8 nmol/min/ mg protein), therefore defining a mut 0 MMA phenotype. Direct sequencing of genomic DNA showed G-to-A transition at position 323 (c.323G > A) and C-to-T transition at position 1741 (c.1741C > T), respectively.
The patient received conventional therapy (dietary management, L-carnitine supplementation, and oral antibiotics) with peritoneal dialysis after admission. His serum ammonia levels fell (from 475 μg/dL to 37 μg/dL) and metabolic acidosis was corrected (pH, from 7.29 to 7.44; anion gap, from 20.2 mmol/L to 13.2 mmol/L) in 48 hours. However, the patient had persistently elevated serum levels of C3 (maximum of 31.70 μM), which failed to respond to conventional therapy. Furthermore, poor feeding, poor growth (his weight showed an increase of 142 g in the 1 st month of admission) and skin erosions, which progressively developed on the face, trunk, buttocks and 4 extremities, were found during the 1 st month of admission despite aggressive management with conventional therapy. After 1 month, GH therapy was prescribed. Subsequently, the patient's weight showed obvious increases in the 2 nd and 3 rd months of admission ( Figure 1 ). His appetite and skin erosions also gradually improved after GH therapy.
Patient 2
This female neonate was born to healthy non-consanguineous Taiwanese parents at 38 weeks of gestation and weighed 2,900 g. The 1
st MS/MS newborn screening performed at 2 days of age showed elevated serum level of C3 (12.44 μM) and elevated C3/C2 ratio (0.81). The 2 nd MS/MS test performed at 5 days of age showed a lower serum level of C3 (8.99 μM) and lower C3/C2 ratio (0.67). However, the 3 rd test performed at 7 days of age showed an unusually elevated serum level of C3 (14.98 μM) and elevated C3/C2 ratio (1.86). The patient was asymptomatic until 8 days of age, and recurrent vomiting subsequently presented. MMA was highly suspected, and the patient was immediately referred to our hospital for confirmatory testing and management.
The results of the laboratory investigations performed on admission are summarized in Table 1 , and mut 0 type MMA was the diagnosis. The patient received conventional therapy with peritoneal dialysis after admission. Her serum ammonia levels fell (from 634 μg/dL to 47 μg/dL) and metabolic acidosis was corrected (pH, from 7.29 to 7.41; anion gap, from 22.4 mmol/L to 13.4 mmol/L) in 45 hours. The difference in management from that of patient 1 was that GH therapy was immediately prescribed on admission, and her weight subsequently showed significant increases, in contrast to that of patient 1 during the 1 st month of admission ( Figure 1 ). Slight skin erosions were found over the perianal area, but were much improved after intensive skin care.
Patient 3
This female neonate was born to healthy nonconsanguineous Taiwanese parents at 38 weeks of gestation and weighed 2,652 g. Shortness of breath with elevated serum level of C3 (16.65 μM) and elevated C3/C2 ratio (0.58) detected by MS/MS newborn screening were noted at 3 days of age. She was referred to our hospital for confirmatory testing and management.
On admission, she was dehydrated, lethargic and showed muscular hypotonia. The results of laboratory investigations performed on admission are summarized in Table 1 , and mut 0 type MMA was the diagnosis. The patient received conventional therapy with peritoneal dialysis after admission. Her serum ammonia levels fell (from 603 μg/dL to 86 μg/dL) and metabolic acidosis was corrected (pH, from 7.09 to 7.35; anion gap, from 32.2 mmol/L to 14.2 mmol/L) in 41 hours. GH therapy was immediately prescribed on admission, and her weight subsequently showed significant increases, in contrast to that of patient 1 during the 1 st month of admission ( Figure 1 ). Slight skin erosions were found over the perianal area, but were much improved after intensive skin care.
Patient 4
This male neonate was born to healthy non-consanguineous Taiwanese parents at 37 weeks of gestation and weighed 2,780 g. At 3 days of age, shortness of breath, poor feeding, and lethargy were noted at the hospital where he was born. Laboratory tests performed there showed the following: white blood cell count, 9,500/mm 3 ; hemoglobin, 13.5 g/dL; platelet count, 330,000/mm 3 ; alanine transaminase, 43 IU/L; aspartate transaminase, 90 IU/L; blood urea nitrogen, 3.0 mg/dL; creatinine, 0.7 mg/dL; blood glucose, 25 mg/dL; serum ammonia, 750 μg/dL; arterial blood gas, pH 7.10; anion gap, 31 mmol/L. These laboratory findings were compatible with organic acidemia, and at that time, elevated serum level of C3 (12.39 μM) and elevated C3/C2 ratio (0.77) were detected by MS/MS newborn screening. The patient was immediately referred to our hospital for confirmatory testing and management.
The results of the laboratory investigations performed on admission are presented in Table 1 , and mut 0 type MMA was the diagnosis. Of note, this patient received conventional therapy with hemodialysis, which was different from patients 1, 2 and 3. His serum ammonia level fell (from 650 μg/dL to 73 μg/dL) and metabolic acidosis was corrected (pH, from 7.28 to 7.36; anion gap, from 24.0 mmol/L to 14.4 mmol/L) in 25 hours. GH therapy was also immediately prescribed on admission, and his weight subsequently showed significant increases, in contrast to that of patient 1 during the 1 st month of admission (Figure 1 ), and no skin erosions were found.
The 4 neonatal patients with mut 0 type MMA were identified through MS/MS newborn screening for elevated C3 levels. Conventional therapy included dietary management (with the special formula XMTVI Analog™, a methionine-, threonine-, valine-free and isoleucine-low powdered infant formula, from SHS, Liverpool, Merseyside, UK), L-carnitine supplementation (100 mg/kg/day), and oral antibiotics (metronidazole, 20 mg/kg/day). GH therapy, 0.6 IU/kg/week subcutaneously (Genotropin ® ; Pfizer, New York, NY, USA) was prescribed for patient 1 after 1 month of admission (on the 31 st day of admission), and was prescribed at the same dose for patients 2, 3 and 4 on the 1 st day of admission. For each patient, an informed written consent was signed by at least 1 parent. C3 level was analyzed by MS/MS at the Chinese Foundation of Health every day.
Results
For patient 1, his weight showed an increase of 834 g in the 2 nd month and 970 g in the 3 rd month of admission, and the skin erosions gradually improved after GH therapy. For patients 2, 3 and 4, their weights showed significant increases in the 1 st month of admission (817 g, 701 g and 752 g, respectively), and they did not experience any deterioration in their condition, in contrast to what was observed in patient 1. The lengths of hospital stay for patients 1, 2, 3 and 4 were 81 days, 37 days, 35 days and 34 days, respectively, and their weights at discharge were 4,650 g, 3,827 g, 3,391 g and 3,543 g, respectively. Serum levels of C3 gradually decreased in patients 1 and 2; however, elevated serum levels of C3 with fluctuations were found in patients 3 and 4 ( Figure 2 ).
Discussion
The management of mut 0 type MMA remains difficult. With the conventional therapy of diet control, L-carnitine supplementation and oral antibiotics, mortality is high and long-term complications are common. 1 Poor growth, one of the most common complications in patients with MMA, may be caused by both chronic illness and severely restricted protein diets. 10, 11 Many patients with MMA are less than 3 standard deviations below the norm for both length and weight. 9 Some children had documented GH deficiency ascribed to brain damage, metabolic or nutritional perturbation. 9 Therefore, GH deficiency may be an etiologic factor in the deteriorating condition seen in patients with MMA. 9, 10 Clinically, GH, due to its anabolic effect, has been shown to decrease wholebody catabolism, increase protein synthesis, accelerate wound healing, reverse growth arrest, and reduce the length of hospital stay in severely burned children. [12] [13] [14] Based on this background, GH therapy appears to be an important alternative for patients with MMA.
The clinical course of patient 1, initially managed with conventional therapy, was complicated with poor feeding, poor growth, and intractable skin erosions despite aggressive management. After 1 month of poor response, GH therapy was prescribed, and subsequently, his clinical condition was much improved. In contrast, patients 2, 3 and 4 received GH therapy immediately after admission, and subsequently, their condition did not deteriorate, which is in sharp contrast to the course of patient 1. The improvement in the clinical condition of the neonatal patients with MMA confirmed our thoughts on the effectiveness of GH therapy.
Elevated serum levels of C3 were persistently found after GH therapy in patients 3 and 4. The metabolic effects of GH therapy on reducing serum C3 levels seem to be indeterminate, although decreased serum levels of C3 were gradually found in patients 1 and 2.
Notably, both patients 3 and 4 demonstrated much clinical improvement after GH therapy despite persistently elevated serum C3 levels. Theoretically, higher serum levels of C3 indicate more severe illness. However, our clinical findings seem to show that elevated serum C3 levels are unrelated to the clinical manifestations of patients with MMA. Thus, the relationship between serum C3 level and the clinical manifestations of MMA remains to be determined.
Liver transplantation is considered to increase metabolic homeostasis and protect against metabolic decompensation in patients with MMA. It can provide an improvement in quality of life due to the mitigation of protein restriction, decreasing frequency of acute decompensation, and alleviation of the state of the disease. 15 Successful liver transplantation has been reported in infants with a median age of 7.4 months and median weight of 5.8 kg. 16 Growth improvement of patients with MMA resulted in the clinical benefit of these patients being able to undergo liver transplantation at an earlier age. Patients 1, 2 and 3 have undergone liver transplantation, and are currently doing well.
Our clinical findings suggest that GH therapy has potentially beneficial effects in neonatal patients with MMA, and we hope that our experience can provide some preliminary data so that more research can be focused on GH therapy in patients with MMA. Nevertheless, determining the optimal doses of GH therapy and the long-term prognosis for those with poor growth will require extensively controlled studies.
